Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Other Non Operating Income (2020 - 2026)

Tango Therapeutics has reported Other Non Operating Income over the past 6 years, most recently at $1.4 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 6.5% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $4.1 million, down 46.54%, while the annual FY2025 figure was $4.1 million, 46.54% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $1.4 million at Tango Therapeutics, up from $705000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $2.2 million in Q1 2024 and troughed at -$81000.0 in Q4 2021.
  • A 5-year average of $943400.0 and a median of $1.0 million in 2022 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: tumbled 4150.0% in 2021 and later skyrocketed 2689.36% in 2023.
  • Year by year, Other Non Operating Income stood at -$81000.0 in 2021, then surged by 1293.83% to $967000.0 in 2022, then soared by 113.13% to $2.1 million in 2023, then fell by 28.38% to $1.5 million in 2024, then decreased by 6.5% to $1.4 million in 2025.
  • Business Quant data shows Other Non Operating Income for TNGX at $1.4 million in Q4 2025, $705000.0 in Q3 2025, and $910000.0 in Q2 2025.